- Home
- WIA vs LRMR Comparison
WIA vs LRMR Comparison
Compare WIA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- LRMR
- Stock Information
- Founded
- WIA 2003
- LRMR N/A
- Country
- WIA United States
- LRMR United States
- Employees
- WIA N/A
- LRMR N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- LRMR Health Care
- Exchange
- WIA Nasdaq
- LRMR Nasdaq
- Market Cap
- WIA 191.0M
- LRMR 183.8M
- IPO Year
- WIA N/A
- LRMR N/A
- Fundamental
- Price
- WIA $8.19
- LRMR $2.25
- Analyst Decision
- WIA
- LRMR Strong Buy
- Analyst Count
- WIA 0
- LRMR 8
- Target Price
- WIA N/A
- LRMR $19.63
- AVG Volume (30 Days)
- WIA 39.2K
- LRMR 1.3M
- Earning Date
- WIA 01-01-0001
- LRMR 04-30-2025
- Dividend Yield
- WIA 12.29%
- LRMR N/A
- EPS Growth
- WIA N/A
- LRMR N/A
- EPS
- WIA N/A
- LRMR N/A
- Revenue
- WIA N/A
- LRMR N/A
- Revenue This Year
- WIA N/A
- LRMR N/A
- Revenue Next Year
- WIA N/A
- LRMR N/A
- P/E Ratio
- WIA N/A
- LRMR N/A
- Revenue Growth
- WIA N/A
- LRMR N/A
- 52 Week Low
- WIA $7.56
- LRMR $1.61
- 52 Week High
- WIA $8.91
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- WIA 48.39
- LRMR 54.28
- Support Level
- WIA $8.13
- LRMR $1.80
- Resistance Level
- WIA $8.21
- LRMR $2.33
- Average True Range (ATR)
- WIA 0.06
- LRMR 0.19
- MACD
- WIA -0.00
- LRMR 0.03
- Stochastic Oscillator
- WIA 47.37
- LRMR 86.67
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.